Design and Synthesis of Dual Opioids/NPFF Ligands as Novel Analgesics with Reduced Tolerance Potential by Yi, John N.
University of Mississippi
eGrove
Honors Theses Honors College (Sally McDonnell BarksdaleHonors College)
2016
Design and Synthesis of Dual Opioids/NPFF
Ligands as Novel Analgesics with Reduced
Tolerance Potential
John N. Yi
University of Mississippi. Sally McDonnell Barksdale Honors College
Follow this and additional works at: https://egrove.olemiss.edu/hon_thesis
Part of the Biochemical and Biomolecular Engineering Commons
This Undergraduate Thesis is brought to you for free and open access by the Honors College (Sally McDonnell Barksdale Honors College) at eGrove. It
has been accepted for inclusion in Honors Theses by an authorized administrator of eGrove. For more information, please contact egrove@olemiss.edu.
Recommended Citation
Yi, John N., "Design and Synthesis of Dual Opioids/NPFF Ligands as Novel Analgesics with Reduced Tolerance Potential" (2016).
Honors Theses. 468.
https://egrove.olemiss.edu/hon_thesis/468

!! i!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2016 
John N Yi 
ALL RIGHTS RESERVED 
!! ii!
 
 
 
 
 
 
ACKNOWLEGEMENTS 
 
 I would like to first thank Dr. Christopher McCurdy providing me the chance to work 
in his lab. I am grateful to Dr. McCurdy for trusting me by challenging me with an 
opportunity not usually available to undergraduate students. I also thank Dr. Stephen Cutler 
for helping me find a lab where I feel at home. 
 My work would not be possible at all without the help of the post-docs. Particularly, I 
thank Dr. Marco Mottinelli for his patience and support during the second and final stages of 
my experimental chemistry. Any compliment towards this thesis is indicative of his standards 
and teachings. I would also like to acknowledge Dr. Coco Kapanda for his guidance in 
helping me start my independent research in the initial stage of my experimental chemistry.  
That being said, I would also like to extend my thanks to the other members of the 
McCurdy group such as Kelsey McPherson, Dr. Walid Alsharif, Kareem Galal, Heba Agha, 
and John Fortner for making it a joy to go to work every day.   
Although they may not remember much of me, I would like to acknowledge Dr. Ajay 
Yekkirala at Harvard Medical School/Boston Children’s Hospital and Dr. Ike Eriator at the 
University of Mississippi Medical Center. Both men helped contextualize the nature of my 
research while also inspiring my future in the health profession field. I cannot thank them 
enough for taking time out of their busy schedules and have meaningful discussions with me. 
 Finally, I would like to thank the faculty at the Sally McDonnell Barksdale Honors 
College for their unending support over my four years here at the University of Mississippi. 
!! iii!
 
ABSTRACT 
 
JOHN N YI: Design and Synthesis of Dual Opioid/NPFF Ligands as Novel Analgesics with 
Reduced Tolerance Potential 
(Under the direction of Christopher R. McCurdy) 
 
 
 Opioid use has become prevalent in today’s culture. As a treatment for acute and 
chronic pain, opioids permeate in the public sphere as a seemingly easy solution. However, 
problems that come from the increased use of opiates, especially in the last fifteen years, 
have shown detrimental effects in society. Not only are all opioid-based analgesics 
considered addictive, but the nature of such painkillers also enables a phenomenon known as 
tolerance, where the body adapts to the use of exogenous opioids. This creates a situation 
where a more potent dose of painkiller is required for the same analgesic effect.  
 The focus of this research was to synthesize possible dual-acting opioid receptor 
agonists and NPFF antagonists through multi-step organic reactions. The neuropeptide FF, or 
NPFF, receptor system is theorized to work in conjunction with the opioid receptor system to 
modulate the body’s pain and pain relief functions in a homeostatic manner. The creation of a 
compound with that enhances opioid activity while minimizing NPFF participation may lead 
to analgesics with reduced abuse and tolerance capabilities. The design and synthesis of the 
compound was inspired by changes to the structure of previously tested molecules. Using 
VBJ192 as a comparative model, the aromatic ring on the piperidine nitrogen was replaced 
with a cyclohexane ring to test changes to opioid/NPFF receptor affinity and activity. Final 
compound JY08 showed greater selectivity for and higher activity at the µ opioid receptor 
subclass. 
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CHAPTER 1  
INTRODUCTION 
 
1.1 BRIEF HISTORY OF PAIN MANAGEMENT 
 Pain is an integral theme of the human condition. On an individual scale, humans are 
born from the pain of their mothers. In one’s lifespan, a person experiences pain as an 
important part of conditioning and learning, not to also mention as a consequence of an aging 
body. At the end of their lives, most people will be in pain when they die.  
Pain also plays an important role in Judeo-Christian theology. When Adam and Eve 
were cast out of Eden, pain was used as a form of punishment in both men’s labor in the field 
and women’s childbirth. Pain was also viewed as a form of self-vindication and an 
expression of repentance from sin.  In the New Testament, the Son of Man was brutally 
tortured and crucified for the salvation of all mankind as a consequence of sin.  
Furthermore, evidence can be found throughout human history that shows that ancient 
civilizations took notice of this permeating matter and sought to find a solution to treat 
physical pain. Around 4000 BC, the Sumerians had already found a way to isolate opium 
from the plant for medicinal use.1 Other civilizations during the same period have recorded 
use of painkilling agents. Egyptian papyri that date back to this time period is known to have 
incorporated pain treatment information.1 In India, the Rigveda text, thought to have been 
written as far back as 4000 BC, commented on various analgesic agents still used today. In 
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Chinese lore, pain was noted as an imbalance between the yin and yang energies and treated 
with acupuncture.1 It is in the scope of recent human history that innovations in the 
management of pain have seen remarkable improvement.  
Specifically, the 19th century saw notable progress in the use of opioid-based 
painkillers to treat various maladies. A more scientific term for narcotics, opioids gained 
prevalence in Western medicine as a result of two events. First, Friedrich Wilhelm Serturner 
discovered morphine, a potent painkiller derived from the poppy plant1. Second, society 
widely adopted the hypodermic syringe as a means of administering drugs1. In the American 
Civil War, soldiers actually used both morphine and hypodermic syringes to self-administer 
the drug as a result of battle wounds. The lack of a standard in the administration of the drug 
caused many soldiers to become addicted to the painkiller, earning addiction the name of the 
“soldier’s disease.”1  
In the advent of the 20th century, the Pure Food Act in 1906 was partially enacted as a 
response to extensive inclusion of opioid-based drugs into childhood remedies like Dover’s 
Powder and Mrs. Winslow’s Soothing Syrup. This law ended the over-the-counter 
availability of opiates, permitting access of the drugs only through medical prescriptions. 
However, this did not stop the public’s insatiable appetite for opium. In a measure to counter 
the increased usage of unregulated opium, Congress passed the Narcotic Control Act in 1914 
to regulate the import and distribution of opioid medication in the United States. As the 
number of people using painkillers continued to grow, the Bureau of Narcotics became 
concerned with the health implications of addicts and abusers. In 1942, nalorphine became 
the first drug to reverse the effect of narcotics. Later, naloxone was the first discovered pure 
and effective antidote against opioid overdose.1 
!! 3!
The latter half of the 20th century saw rapid progress in the opioid research. In the 
1950s, the American Medical Association validated the use of narcotics as a way to treat 
addicted patients as a form of therapy. Identification and discovery of endogenous opioids 
led to the discovery of opioid receptors in the body. Knowledge that the opioid receptors 
were largely localized in the central nervous system (CNS) was critical in procedures that 
targeted those receptor sites. The directed administration of opioids into the CNS used a 
much less amount of medicine for the same painkilling effect, decreasing the side effects 
attributed with larger doses. In the 1980s, the government loosened restrictions on opioids, 
allowing for wider use beyond pain relating to only cancer. By the end of the 20th century, 
the prevalence of new opioid-based drugs in pain management treatment options paralleled 
the increased number of opioid-drug users in the United States and the world.  
In the 21st century, the US Congress declared the years from 2001 to 2010 as the 
“Decade of Pain Control and Research.” However, even in current medicine, it is impossible 
to conclusively measure and appropriately treat pain. Clinically, pain only exists through 
communication between the patient and provider.2 Pain management literature conveys good 
physicians should strike the right balance between opiophobia (irrational fear or 
unwillingness to use opioids for pain treatment) and liberal prescription so that medication 
can be available to pain patients that truly need them without promoting abuse, misuse, and 
addiction.2, 3 One textbook states that the ethical responsibility of physician is to “ensure [the] 
use for the right purpose, right patient, and at right time.”3 In order to adhere to such 
idealistic aspirations, modern physicians are equipped with the large array of opioid-based 
drugs. 
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1.2 TYPES OF OPIOIDS 
The term “opioids” is the more scientific term for drugs colloquially known as 
narcotics and encompasses an array of opioid-based analgesics. Opioids are divided based on 
their origin into three classes: natural, semi-synthetic, and synthetic. 
Natural opioids are derived from opium, the dried extract obtained from poppy fruit.1, 
4 These natural drugs that originate from the opium poppy are also called “opiates.” The 
opium poppy extract serves as the basis for alkaloids, or naturally organic nitrogen-
containing bases, such as morphine and codeine. Morphine was not only the first alkaloid 
isolated from opium, but it is also believed to be the first isolation of an active ingredient of a 
plant.1 
Semi-Synthetic drugs are derived from the naturally occurring opium alkaloids. 
However, these compounds do not occur naturally in nature like morphine. Examples include 
heroin and oxycodone. Heroin was synthesized by adding two acetyl groups on the morphine 
molecule.5 Ironically, it was actually marketed as a safer alternative to morphine in the early 
1900s. Although it was initially thought to be a non-addictive substance, it is now a heavily 
controlled Schedule I drug.1 
Synthetic opioids such methadone, demerol, and fentanyl are completely synthesized 
from other chemicals and molecules that do not come from opium.1, 6 These painkillers were 
generally discovered later than natural and semi-synthetic opioids after greater drug research. 
Demerol was discovered in 1939 and mistakenly marketed as another non-addictive opioid 
analgesic.1 Fentanyl is widely used in surgical rooms and emergency situations due to its 
relatively rapid onset and short half-life. Methadone was used after 1946 for addicts 
!! 5!
withdrawing from heroin, but still include side effects attributed to other opioids such as 
sleepiness, vomiting, and dizziness.6, 7 However, it is important to note that all opioids have 
the capability of being abused and causing great bodily harm. 
 
1.3 OPIOID ABUSE IN SOCIETY 
Opioid addiction has been steadily rising in the new millennia. Globally, it seems that 
there were more than 15.5 million opioid-dependent people in 2010.8 These figures also 
include illicit drugs such as heroin, and seem to be rising every year across the world. In the 
United States alone, the number of painkiller prescriptions, on average is half of the 
population per state. In some Southern states such as Mississippi, the number of painkiller 
prescriptions outnumber (are above 100) the amount of people (per 100) in the state.9 
Overdose rates were highest among people aged 25-45 years.10 It has also been found that as 
many as 1 in 4 people who obtain opioids for long-term cancer pain struggle with addiction.10 
Those affected by opioid dependence prior to incarceration have shown to be at high-risk for 
abuse, mortality and reincarceration after being released11, 12. 
Although the amount of pain Americans report has not changed from 1999, the sales 
of prescription opiates in the United States have tripled from 1999-2014.9 In the United 
States, it is estimated that 100 million people struggle with chronic pain. While the sales of 
medication are more than triplicate, overdosing on any drug has become the leading cause of 
untimely death in the United States, with opioids being the leading cause of accidental 
overdose and mortality.3 Since 1999, deaths from prescription painkiller overdoses have 
increased more than 400% among women and 265% among men.13 In 2014, there were 
approximately 52 deaths per day from prescription opioids. In terms of deaths per 100,000, 
!! 6!
drug overdose deaths involving opioids from 2000-2014 have risen from around 2 to 8.5 
deaths per 100,000 populations.14  
Economically, chronic pain and painkiller abuse have large consequences. In early 
2016, the Obama administration pledged to offer US $1.1 billion dollars to fight heroin and 
painkiller abuse.15 The National Institute of Health (NIH) predicts that the United States 
spends over US $100 billion on medical expenses, lost wages, and other costs relating to 
pain.1 The NIH also estimates that 12.7% of employees lose productive time due to pain, 
resulting in a startling $61.2 billion dollar loss in productivity nationally.1  
Along with the increase in opioid users and abusers, the crackdown on prescription 
volume by varying governing bodies are shown to have caused a spike in heroin users as an 
unintended consequence.16 Scientifically called diacetylmorphine, heroin was marketed in 
the 19th century and considered a safer alternative to morphine. Public awareness eventually 
attached the appropriate stigma to heroin as a much more dangerous opioid. Some studies 
assert that recent governmental initiatives making prescription painkillers harder to acquire 
have unknowingly lead to a rise in heroin use.16 However, other literature suggests that this 
relationship is merely a correlation, and that it is still too early to attribute causality.5  
Opioid-drug addiction is currently and has been an important issue not only in the 
United States, but also all over the world. Opioid-based therapies have been historically 
recorded to tackle pain. In the last 200 years, innovations in opioid-based drugs have 
stimulated policy decisions in response to physiological and social issues correspondent with 
abuse and addiction. Therefore, in order to design better drugs to combat opioid-drug abuse 
while also respecting the necessity of analgesics in the treatment for pain, it is important to 
understand the physiological body mechanisms involved in pain and analgesia. 
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CHAPTER 2 
BACKGROUND 
 
2.1 OPIOID RECEPTORS 
The opioid receptors are all inhibitory G-protein coupled receptors located on the 
plasma membrane of select cells. Specifically, opioid receptors seem to be localized in the 
spinal cord and brain. Opioid receptors in the dorsal horn of the spinal cord seem to have a 
central role in the modulation of pain. For this reason, segmental analgesia is possible 
through the spinal administration of opioids to targeted areas along the spine.  In the brain, 
the opioid receptors are highly expressed in the cerebral cortex and cerebellum.17 Opioid 
receptors are also distributed in the peripheral nervous system (PNS) and are involved in the 
regulation of gastrointestinal function such as increased absorption of water from stools and 
spasticity of the gut.17 Activation of these receptors in the PNS by exogenous opioid-based 
drugs lead to the unfortunate side-effect of constipation and these same receptors seem to be 
regulated by inflammation and the immune system.  
The opioid receptor system can be subdivided into its three classical subtypes: mu, 
kappa, and delta. Although a fourth receptor subclass known as the nociception opioid 
receptor also exists, it is generally not focused for study like the other three classic subtypes.  
The mu-opioid receptor, or MOP, is the most commonly studied subclass of the 
opioid receptor system. Named after morphine, the drug first used to discover the receptor, 
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the MOP is commonly targeted by exogenous drugs for painkilling effect.4 Many, if not 
most, opioid-based medicines such as morphine, fentanyl, and oxycodone selectively bind to 
the MOP subclass. The MOP seems to be localized in the cortex, thalamus, striosomes, 
periaqueductal grey, and rostral ventromedial medulla of the brain and the substantia 
gelanitosa in the spinal cord.18 It also seems to be located in peripheral sensory neurons and 
the intestinal tract19, 20 MOP activation via an agonist will cause analgesia and euphoria but 
can also cause physical dependence, respiratory depression, and possible vasodilation.18, 21 
The kappa-opioid receptor, or KOP, was named after ketocyclazocine, the first drug 
shown to bind to the KOP.4 The KOP seems to be localized in the hypothalamus, 
periaqueductal gray, and clastrum or the brain, the substantia gelatinosa of the spinal cord, 
and peripheral sensory neurons.19, 20 Activation of the KOP via an agonist can cause 
analgesia, anticonvulsive effects, and neuroprotection, but it can also cause depression, 
dissociative hallucinations, diuresis, and dysphoria.19, 20 For this reason, KOP agonists are 
generally not used as analgesics in order to avoid the dangerous side effects. However, 
endogenous KOP agonists have been identified in the human body, which could infer that the 
KOP selective drugs may have utility in a clinical setting.  Moreover, KOP agonists may 
have possible therapeutic uses as treatment for MOP selective opioid drug addiction due to 
its nature as a punisher.21, 22 
Lastly, the delta-opioid receptor, or DOP, was named after the vas deferens of the 
tissue in which it was first found.23 The DOP seems to be localized in the pontine nuclei, 
amygdala, olfactory bulbs, and deep cortex of the brain as well as peripheral sensory 
neurons. 19, 20 Activation of the DOP via an agonist can cause analgesia and antidepressive 
effects along with convulsant effects and physical dependence.19, 20 Nevertheless, selective 
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and potent DOP agonists have shown to have promising futures due to their avoidance of 
side effects associated with the MOP and their superb pharmacological profile and 
bioavailability.24 
  
2.2 NPFF RECEPTORS 
 The neuropeptide FF (NPFF) receptor system has not been as widely studied as the 
opioid receptor system. Nevertheless, NPFF receptors may play a critical role in the body’s 
response toward pain and its homeostatic regulation. Like opioid receptors, the NPFF 
receptors are also G-protein coupled receptors that utilize intracellular signal transduction 
towards various cellular goals.25  
The NPFF system contains two subtypes: NPFF1 and NPFF 2. NPFF1 is broadly 
distributed in the CNS with particularly high localization in the limbic system and 
hypothalamus. On the other hand, NPFF2 seems to be present in the superficial layers of the 
spinal cord. Together, the NPFF receptors seem to have a complex role in modulating pain in 
the body with the opioid receptors.25  
Much is left to be learned about the NPFF system. However, studies on opioid 
addiction and tolerance have revealed possible functions that the NPFF system manifests 
during the body’s pain response.25, 26  
 
2.3 OPIOID ADDICTION 
Opioid drug addiction has a physical and psychological component, which makes it a 
difficult public health issue to challenge. Physical dependence is the predictable 
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physiological response to chronic opioid exposure characterized by development of 
withdrawal syndrome.27, 28 This burden seems further compounded psychosocial factors. 
Physiologically, it is very easy for the body to get addicted to these painkillers. 
Although the human body has its own endogenous painkillers such as enkephalins and 
endorphins, the chronic use of exogenous drugs such as morphine creates a new 
physiological environment for the body to adapt. The body will then predictably stop 
producing its natural endogenous analgesics, meaning that discontinuation of the exogenous 
painkiller will present a long refractory period in which the body will not produce the 
endogenous compounds. The higher sensitivity to pain stimuli that results after the 
discontinuation of opioids is known as opioid-induced hyperalgesia (OIH).28   
Opioids are also very susceptible to induce body tolerance. Tolerance is the state of 
adaptation in which exposure to the same dose of the drug results in a diminution of one or 
more of the drug’s effects over time.3, 29 In other words, higher doses of drugs, such as 
painkillers, are needed to achieve the same effect. Opioid effects are also reinforced by the 
brain’s reward center. In reward system of the Ventral Tegmentum Area, MOP activation 
inhibits γ-aminobutyric acid (GABA) release from interneurons.3, 21 This disinhibition of 
dopamine-releasing neurons would increase dopamine neurotransmitter resulting in pleasure 
and possible addiction.  
Interestingly, one experiment found that administration in model animals of heroin 
and RF9, a MOP selective agonist and an NPFF antagonist respectively, maintained the 
analgesic activity while also blocking the OIH and preventing tolerance.27 RF9’s non-
selective binding toward both NPFF receptor subtypes seems to indicate that both are 
necessary for proper antiopioid activity mediation.27 The utilization of an opioid agonist and 
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an NPFF antagonist could possibly lead to breakthrough drugs that present painkilling effects 
without adverse side effects such as OIH and tolerance.  
 However, it is important to note that addiction also has a psychological component 
that must also be appropriately addressed. Addiction is influenced by genetic, psychological, 
and environmental factors. Opioid drug addiction also presents social issues such as the 
stigma of addicts in the family and the increased risk of depression and suicide.3 Therefore, 
although the future for novel drug discovery is promising, special attention should also be 
preserved in the treatment of opioid drug addicts in the scope of a holistic biopsychosocial 
model of modern health care.  
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CHAPTER 3 
AIM AND OBJECTIVES 
 
3.1 AIM OF THE PROJECT 
The aim of this project is to synthesize a possible dual-active opioid-NPFF ligand 
based on data previously collected by Dr. McCurdy’s group. The experiment studied the 
effects of removing aromaticity located with the benzene ring attached to the piperidine 
nitrogen (JY08, Figure 3-1) of a previously successful compound, VBJ192 (Figure 3-2).  
 
 
Figure 3-1. Target Compound JY08 bearing a cyclohexyl moiety on the piperidine ring. 
Multistep organic synthesis was used to generate the target compound JY08 (Figure 
3-1). After the final step, the compound was tested in a variety of biological assays to 
determine ligand affinity and functional activity at the desired receptors.   
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Figure 3-2. VBJ192 with Aromatic Ring at Piperidine 
The proposed compound, JY08, was compared with the biological activity profile of 
VBJ192. The latter has shown opioid agonist and NPFF antagonist activity in in vitro and in 
vivo testing. Furthermore, VBJ192 proved to be able to cross the blood-brain barrier, a 
characteristic essential for ligands that bind with receptors localized in CNS.   
 
3.2 PROJECT RATIONALE: LIPINSKI’S RULE 
 JY08 was specifically designed to be a nonpeptidic ligand for the opioid and NPFF 
receptors and as such, it has expected strong pharmacokinetic advantages over its peptidic 
counterparts. In addition, JY08 was designed with respect to the Lipinski’s rule of five, 
which are guidelines for a more probable generation of orally bioavailable drugs. 
Lipinski’s rules state that a compound should be below 500 Da, or 500 g/mol. The compound 
should not contain more than five hydrogen bond donors, such as N-H and O-H, and at the 
same time should not have more than ten hydrogen bond acceptors which include all 
nitrogens and oxygens atoms in the structure. Lastly, the n-octanol-water partition coefficient 
(LogP) that determines lipophilicity should not be greater than 5. Greater LogP values reflect 
N
N
H
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a higher lipophilicity. Compounds should not only be too lipophobic so that they can diffuse 
through the phospholipid membrane of the intestinal cells toward intestinal absorption. At the 
same time, compounds should also not be too lipophilic, as a high lipophilicity is associated 
with low aqueous solubility. As a matter of fact, only the fraction of drug actually in solution 
in the intestinal lumen can diffuse through the cells and be absorbed. Hence, a high 
lipophilicity is generally reflected into poorly absorbed compounds. 
Therefore, we sought to follow the guidelines set by Lipinski’s Rule. The nonpeptidic 
nature allows the compound to be quite small, increasing the odds of it being able to pass 
through the blood-brain barrier. JY08 has a molecular mass of 402.59 Da, under the 500 Da. 
With the guanidine and piperidine nitrogens, our target compound also only has four H-bond 
donors and two acceptors. Lastly, the CLogP is 5.305, slightly above the threshold set in the 
Lipinski’s rules. However, the molecule contains groups expected to be completely 
protonated at physiological pH. As a consequence, LogD would be a better descriptor of 
solubility compared LogP. It is important to note that these rules are merely strategies to 
achieve positive oral bioavailability. Since Lipinski’s Rule is merely a guideline, breaking 
one or even two rules can still result in favorable oral bioavailability. 
 
3.3 PROJECT RATIONALE: MERGING OPIOID & NPFF STRUCTURES 
 JY08 was proposed as a possible dual-activity drug, otherwise known as a designed 
multiple ligands (DML). Our final compound took inspiration from previous successful 
efforts to combine scaffolds from opioid agonists and NPFF antagonists. Synthesis of a 
successful opioid/NPFF DML would hypothetically maintain analgesic effect while also 
preventing tolerance and hyperalgesia.  
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 A study by Journigan et al. found an effective starting template for creating optimal 
NPFF antagonist. The NPFF1-R antagonist (Figure 3-3) was proposed to be chosen from a 
template due to its NPFF antagonist activity and its non-peptide nature.25, 30 Therefore, a 
scaffold based on NPFF1-R would provide the NPFF antagonist activity in the combined 
structure.  
 
Figure 3-3. NPFF1-R Selective Antagonist as the NPFF Scaffold. 
 On the other hand, a scaffold based on SNC80 and BW373U86 DOP agonists was 
chosen because the previously created guanidine-piperidine template is able to tolerate the 
phenyl ring on the diarlmethylideine piperidine portion of the agonist.31, 32 The DOP agonist 
structure is shown by compound B in Figure 3-5. The same figure also showed the logical 
merging of both NPFF1-R and the DOP agonist into a novel structure. 
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Figure 3-4. Proposed Opioid/NPFF Merged DML Scaffold from Precursors 
When looked at more closely, compound C in Figure 3-5 closely resembles VBJ192 
when the R-group contains an H. However, unlike VBJ192, JY08 has a cyclohexane 
structure attached to the piperidine region of the compound. There are numerous reasons why 
removing the aromaticity of the phenyl ring is hypothesized to change the biochemical 
properties of the compound. First, by using cyclohexane instead of a benzene ring, the region 
can partake in numerous stereochemical shapes such as the chair and boat conformation. This 
may change the interaction between the ligand and the receptor. The phenyl group is 
theorized to slide into receptors more easily due to the flat and planar nature of the ring 
allowing between pi-pi stacking interactions. It has been reported in literature cases where 
that removing aromaticity could decrease the ability for compounds to cross the blood-brain 
barrier. Even though this would be a detrimental effect, it would enhance understanding of 
the SAR of the ligand. Lastly, changing the aromatic ring into a cycloalkane may possibly 
change the compound from being an agonist to an antagonist. Regardless of the outcome, 
using a cyclic versus an aromatic ring may shed more light into the SAR of the ring 
structures attached at the piperidine.  
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CHAPTER 4 
RESULTS AND DISCUSSION: CHEMISTRY 
 
4.1 WITTIG SALT SYNTHESIS
 
Figure 4-1. Synthesis of JY00 Wittig Salt. 
Benzylbromide and triphenylphosphine were dissolved in toluene, heated, and 
refluxed overnight to produce the Wittig Reagent salt. White powder was easily recovered 
with high yield by simple filtration. Despite being it commercially available, the compound 
could be readily synthesized with no noticeable impact on the overall synthesis.  
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4.2 WITTIG REACTION 
 
Figure 4-2. Wittig Reaction of JY00 toward JY01. 
JY01 was suspended in freshly distilled THF under argon gas at 0 °C. 2.0 eq of LDA 
in THF/n-heptane/ethylbenzene was then added drop-wise slowly, and the entire mixture was 
allowed to stir for half an hour. Subsequently, the compound was allowed to warm to room 
temperature before the introduction of the protected piperidinone and then stirred overnight. 
Initially, purification of the crude reaction mixture was attempted by suspension and 
decantation of the the same mixture in hexane. The filtrate was evaporated and the precipitate 
was subjected to the same procedure until no visible traces of UV-active material could be 
identified by TLC of the filtrate. However, this process was extremely time consuming and 
therefore for later reactions, the crude mixture was dissolved in Hex/EtOAc and purified by 
flash chromatography using a Hex/EoAC (5:5) system.  
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4.3 DEPROTECTION OF PIPERIDINE 
 
Figure 4-3. Deprotection of JY01 toward JY02. 
 TFA was added to a solution of JY01 in DCM and was allow to stir at rt overnight. 
The TFA was then evaporated and a saturated solution of Na2CO3 in water was added 
afterwards. Bubbles were observed along with a color change from orange to dark brown. 
The mixture was allowed to stir until bubbles were no longer seen forming. The mixture was 
extracted with EtOAc to obtain the product in its free base form.  
 
  
 
 
 
 
 
 
 
 
H2
N
N
OO
xs TFA
OOCCF3
!! 20!
4.4 ALKYLATION OF FREE BASE 
 
Figure 4-4. Alkylation of JY02 toward JY03. 
 The alkylation of JY02 in anhydrous DMF in presence of an excess of K2CO3 
proceeded smoothly by stirring overnight under heat. Extraction and purification of the 
compound by flash column chromatography yielded the pure product in 72% yield.  
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4.5 BROMINATION AND SUZUKI COUPLING 
 
Figure 4-5. Bromination of JY03 toward JY04 and Suzuki Coupling toward JY05. 
 In the initial procedure, JY03 was dissolved in DCM and ice chilled for half an hour 
under argon gas. Afterwards, the ice was removed and neat Br2 was added. The mixture was 
then stirred for another hour and the formation of the dibromo intermediate was confirmed by 
TLC. A solution of NaOH in MeOH was then added to the reaction mixture. The entire 
mixture was heated over 2.5 hours. Compound was not immediately extracted and placed in 
the fridge. After extraction the following day, mass spectroscopy showed strong peaks at 254 
g/mol instead of the desired 348.33 g/mol region. Analysis on the mass spectroscopy lead us 
to believe that the cyclohexane had been cleaved off somehow during the course of the entire 
reaction conditions. It was theorized that extraction should be done immediately at the end of 
the reaction so the compound would not interact with other compounds in the mixture. Ice 
was also not removed until right before the NaOH was added. 
 The reaction was repeated again in the same conditions until TLC and mass 
spectroscopy confirmed the formation of the dibromo intermediate. A solution of NaOH in 
MeOH was added to mixture and a wispy white gas evolved and the mixture turned a milky 
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cream color. The mixture was then headed for 2.5 hours. Immediately after completion, the 
reaction mixture was extracted with EtOAc and washed with water and brine twice in a 
separatory funnel. Organic layer was dired with sodium sulfate, filtered over filter paper, and 
the subsequent reaction was resumed once the mass spectroscopy confirmed the 348 g/mol 
peak. 
4-Nitrophenylboronic acid was added to JY04 in toluene/ethanol (3:1 ratio) with 
K2CO3. Pd(PPh3)4 catalyst was carefully added to the reaction mixture and the reaction vessel 
was wrapped in tin foil protect the light sensitive catalyst. Mixture was heated in refluxing 
conditions and left to stir overnight. An aqueous work up and purification by flash 
chromatography on silica gel afforded the compound in relatively low yield.  
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4.6 REDUCTION OF THE NITRO GROUP 
 
Figure 4-6. Reduction of JY05 toward JY06. 
Hydrogenation of JY05 at 40 PSI for 4 hours readily afforded the amine JY06. The 
product could be easily recovered removing the catalyst by filtration. Evaporation of the 
filtrate yielded the reduced compound in good yield. 
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4.7 ALKYLATION OF AMINE 
 
Figure 4-7. Coupling of JY06 toward JY07. 
1,3-Bis(tert-butoxycarbonyl)-2-methylthiopseudourea and HgCl2 were added to a 
suspension of JY06 in DCM and TEA. Due to the slow reaction rate, the mixture was stirred 
for a week to achieve completion. An aqueous work up and purification by flash 
chromatography on a silica gel column using Hex/EtOAc (8:2) eluent afforded the desired 
compound as a white powder.  
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4.8 DEPROTECTION TOWARD FINAL COMPOUND 
 
Figure 4-8. Deprotection of JY07 toward JY08. 
2.0 M HCl in diethylether was added to JY07 dissolved in DCM. Mixture was stirred 
overnight at rt. The mixture was subsequently evaporated to give the desired final compound 
JY08 as a white solid powder with relatively high yield.  
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CHAPTER 5 
RESULTS AND DISCUSSION: BIOLOGY 
 
5.1 OPIOID RECEPTOR TEST RESULTS  
 
Figure 5-1. Binding Assay Graphs for Opioid Receptors  
Numbers in the Table 5-1 are extrapolated from the respective receptor subclass 
graphs in Figure 5-1. From the sigmoidal curves, computational calculations elucidate the 
concentration for binding affinity, using naloxone as the overall standard for all subclasses. 
 
Table 5-1. Binding/Affinity Assay for JY08 at Opioid Receptor 
 
 Table 5-1 shows the binding affinity of JY08 to the various opioid receptor 
subclasses. A Ki of 34.29 ± 5.38 nM for MOR reflects JY08’s strong binding affinity for the 
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receptor subclass. In comparison, the Kis of 649.9 ± 117.8 nM at KOR and 1,763 ± 215 nM 
at DOR respectively reflected a lower affinity for JY08. 
 
      
 
Figure 5-2. Functional Assay Graphs for Mu Opioid Receptor 
Numbers in the Table 5-2 are extrapolated from the mu receptor subclass graph. From 
the sigmoidal curves, computational calculations elucidate the concentration for functional 
affinity, using DAMGO as the standard.  
 
Table 5-2. Functional Assay for JY08 for Opioid Receptor  
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EC50 results show moderate functional activity for JY08 at the MOR. The compound 
is shown to be a full agonist. At 721.6   ± 195.0 nM molar concentration, 100% of the 
maximal possible effect of the agonist was seen.  
 
 
5.2 NPFF RECEPTOR TEST RESULTS 
Regrettably, no evaluation of the activity of JY08 at the NPFF receptors could be 
performed due to complications with the assay protocol and the radioligand at the 
BioMolecular Science department. However, biological evaluation of the compound at the 
NPFF receptors has been planned for the near future.  
 
 
5.3 COMPARATIVE ANALYSIS 
Table 5-3. Affinity and Functional Assay for VBJ192 and JY08 
  
Affinity Assay Functional Assay 
Ki (nM) EC50 (nM) [Full Agonist] 
δ κ µ δ κ µ 
VBJ192 120.6 315.5 134.2 194.1 523.8 881.8 
JY08 1,763 ± 215  649.9 ± 117.8  34.29 ± 5.38  - - 721.6   ± 195.0  
 
JY08 was compared against VBJ192 for affinity and functional activity at the opioid 
receptors. For each assay, a lower numbers represent a smaller concentration in nM needed 
for appropriate binding or to exert a predetermined level of activity.  
 The functional assays of JY08 at the DOP and KOP were not performed because the 
Kis  of the compound at those target were above the required threshold. Nevertheless, in the 
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functional assay, JY08 and VBJ192 showed relatively similar concentrations needed to 
activate 50% of the MOR (EC50). Table 5-3 shows that the EC50 of 721.6 nM ± 195.0 nM for 
JY08 is only marginally better than the EC50 of VBJ192, which is 881.8 nM, and that the 
difference is statistically negligible. However, the selective nature of binding of JY08 
towards just the MOR is beneficial for moving towards a drug that avoids side effects 
associated with the other two-receptor subclasses. Therefore, although the functional assay 
showed only a moderate potency of 721.6 ± 195.0  nM at the MOR, its selective binding at 
the MOR is a notable. 
 
Table 5-4. Compound Selectivity Ratio for MOP receptor 
  
Selectivity for µ 
µ/δ µ/κ 
VBJ192 0.90 2.35 
JY08 51.4 18.95 
 
 As shown in Table 5-4, final compound JY08 seems to have nearly 51 fold greater 
affinity for the MOP over DOP and almost 19 fold greater affinity for the MOP over KOP. 
Compared to VBJ192, JY08 has ca. 50 fold greater affinity for MOP over KOP, and ca. 8 
fold greater affinity for MOP over DOP. This data shows that JY08 is a much more selective 
ligand for the MOR than VBJ192. 
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CHAPTER 6 
CONCLUSION 
 
6.1 FUTURE DIRECTION 
 JY08 needs to be tested at NPFF receptors for further analysis of the compound. This 
would allow to further the comparisons with VBJ192. By analyzing the cyclohexyl of the 
compound’s effect on the NPFF receptors, it would be possible to attain better understanding 
of the ring on the piperidine’s SAR and could direct the design of future compounds. 
Furthermore, optimization of chemical schemes used in the synthesis of JY08 would also be 
beneficial, as they could increase experimental yield and determine more efficient parameters 
for every reaction. 
 Since the region where the cycloalkane ring is located is of added interest, exploring 
the position by introducing different cyclic or acyclic saturated chains could be beneficial. To 
achieve this, an optimization of the synthetic scheme could then be advantageous. For 
instance, the use of a CBZ protected piperidine rather than a BOC group would eliminate 
repetitive reactions for arriving at final compounds. A Wittig Reaction using 1-CBZ-
piperidin-4 one instead of n-BOC-4-piperidone, followed by subsequent reactions for 
schemes 5-7 in the JY04 to JY07 synthesis would result in a useful template compound. 
From this template, the piperidine CBZ group could be deprotected and then alkylated to 
introduce the desired substituent, e.g. cyclopentane, cyclobutane or cyclopropane. This 
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would then be followed by deprotection of the BOC groups located at the guanidine group 
resulting in other final compounds. Stocking up on Compound A. of Figure 6-1 for later 
deprotection and alkylation could yield many new compounds in a shorter span of time. 
 
Figure 6-1. Proposed Schemes Using CBZ 
 MES458/CM695 (Figure 6-2) would be another possible compound for comparative 
studies. The guanidine group at the meta (3’) position seems to reinforce greater affinity for 
the opioid receptor binding compared to the para (4’) position of VBJ192. Between MES458 
and VBJ192, MES458’s Ki of 6.58 nM shows roughly twenty times greater affinity for the 
mu receptor than VBJ192’s Ki of 134.2 nM. The cCAMP functional assay shows similar 
differences, where the MES458’s EC50 of 31.44 nM is twenty-eight fold greater than 
VBJ192’s 881.8 nM at the µ opioid receptor. Like VBJ192 and JY08, It is possible that 
removing the aromaticity at the benzene ring on the piperidine nitrogen of MES458 may 
likewise increase selectivity for the mu receptor. This modification could lead to compound 
that is highly selective, strong binding, and more functionally active at the µ-opioid receptor. 
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Figure 6-2. MES458/CM695  
 The shift toward a cycloalkane ring structure rather than an aromatic one has shown 
change in biological properties. This confirms the hypothesis that structural modification of 
these nonpeptidic ligands may have significant effects. Greater study into various other ring 
structures and structural modifications could possibly lead to promising compounds that can 
be further tested and studied toward novel drug discovery. More study into both the opioid 
and NPFF systems could also reveal essential information towards tackling opioid addiction 
and tolerance.  
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CHAPTER 7 
EXPERIMENTAL 
 
7.1 CHEMISTRY 
Unless otherwise stated, the reagent and starting materials were obtained from 
commercial suppliers such as Sigma Aldrich and used without purification. Freshly distilled 
anhydrous THF was prepared from benzophenon and Na+ lump. Pre-coated silica gel GF 
Uniplates (Analtech) were used for the TLC. Column chromatography was performed with 
silica gel 60 from Sorbent Technologies. The MS were recorded on a WATERS ACQUITY 
Ultra Performance LC with ZQ detector in ESI Mode. 1H spectra were obtained on a Bruker 
500 MHz, 400 MHz, or Bruker 400 MHz Ultra Shield. Analytical HPLC was measured on a 
Waters 2695 system and a Waters 996 UV detector. 
 
GENERAL PROCEDURE: 
Benzyltriphenylphosphonium bromide (JY00). Benzylbromide (10.0 ml, 82.7 mmol) and 
triphenylphosphine (21.9 g, 82.7 mmol) were dissolved in toluene (75 ml), and stirred 
overnight under refluxing conditions. Reaction was then allowed to cool to room temperature 
and filtered. The precipitate was washed with diethylether and dried to yield 35.5 g of the 
title material as a white solid in 99% yield. 
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Tert-butyl-4-benzylidenepiperidine-1-carboxylate (JY01). JY00 underwent Wittig 
Reaction. JY00 (15 g, 34.62 mmol) was suspended in freshly distilled THF (ca. 50 ml) under 
Ar (g) at 0 °C. 2.0 M LDA in THF/n-heptane/ethylbenzene (19ml, 38.08 mmol) was added 
drop-wise. The mixture was stirred in ice for 0.5 hours. Afterwards, a solution of N-BOC-4-
piperidone (6.89 g, 34.62 mmol) in freshly distilled THF (35 ml) was added via syringe and 
stirred at 0 °C for further 0.5 hours. The reaction was then allowed to warm to room 
temperature and was left to stir at rt overnight. The mixture was diluted with EtOAc and 
washed with water and brine. The organic layer was dried with sodium sulfate and 
evaporated. The crude compound was purified by flash chromatography on a silica gel 
column using Hex/EtOAc (5:5) as the eluent to give 6.27 g of the title material as a yellow 
oil in 65.8% yield. 1H NMR (400 MHz, CDCl3) δ 7.34 (dd, J = 8.5, 6.5 Hz, 2H, 2 x ArCH), 
7.26 – 7.16 (m, 3H, 3 x ArCH), 6.38 (s, 1H, C=CH), 3.54 (t, J = 5.9 Hz, 2H, CH2CH2N), 
3.43 (t, J = 6.0 Hz, 2H, CH2CH2N), 2.49 (t, J = 6.0 Hz, 2H, CH2CH2N), 2.35 (t, J = 5.9 Hz, 
2H, CH2CH2N), 1.51 (s, 9H, 3 x CH3); 13C NMR (101 MHz, CDCl3) δ 153.7 (C=O), 137.3 
((CH2)2C=CH), 136.3 (ArCCH), 127.8 (2 x ArCH), 127.1 (2 x ArCH), 125.2 (ArCH), 123.5 
(C=CH), 78.4 ((CH3)3CO), 44.4 (CH2CH2N), 43.5 (CH2CH2N), 35.1 (CH2CH2N), 28.1 
(CH2CH2N), 27.4 (3 x CH3); MS (ESI+) 273.17 (M-H)+  
 
 
4-Benzylidenepiperidine (JY02). JY01 underwent deprotection of the BOC group. TFA (20 
ml) was added to a solution of JY01 (6.27 g, 22.78 mmol) in DCM (20 ml) and stirred at rt 
overnight. A saturated aqueous solution of Na2CO3 in large excess was added to mixture 
after TFA was evaporated. Lots of carbon dioxide gas was observed and the color changed 
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from orange to dark brown color.  The mixture was stirred at rt for 4 hours until no further 
gas development could be observed. The mixture was diluted then with EtOAc and washed 
with water and brine. The organic layer was dried with sodium sulfate and evaporated to 
yield 3.44 g of the title material as a yellow oil in 86.5% yield. 
 
4-Benzylidenepiperidine-1-(cyclohexylmethyl)piperidine (JY03). JY02 underwent 
alkylation at the piperidine nitrogen group. JY02 (3.44 g, 19.714 mmol) was suspended in 
anhydrous DMF (20 ml). Cyclohexylmethyl bromide (8.26 ml, 59.16 mmol) and K2CO3 
(8.18 g, 59.16 mmol) were added to the solution and the mixture was stirred at 70 °C 
overnight. The mixture was diluted with EtOAc and washed with water and brine. The 
organic layer was dried with sodium sulfate and evaporated. The crude compound was 
purified by flash chromatography on a silica gel column using Hex/EtOAc (5:5) as the eluent 
to give 3.8 g of the title material as a brown liquid in 71.7% yield. 
 
4-(Bromo(phenyl)methylene)-1-(cyclohexylmethyl)piperidine (JY04). JY03 underwent 
bromination at the double bond. JY03 (1.105 g, 4.10 mmol) was dissolved in freshly opened 
DCM and ice-chilled for 0.5 hours under Argon gas. Then, neat Br2 was added drop-wise 
(0.314 ml, 7.84 mmol), and the mixture was allowed to stir for another 1 hour under Ar (g) at 
0 °C. NaOH (0.998 g, 24.98 mmol) was then dissolved in MeOH and added to the reaction 
mixture via syringe. The mixture was stirred at 48 °C for 2.5 hours. Mixture was diluted with 
EtOAc and washed with water and brine. The organic layer was dried with sodium sulfate 
and evaporated. Reaction yielded 1.25 g of the crude material. 
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1-(Cyclohexylmethyl)-4-((4-nitrophenyl)(phenyl)methylene)piperidine (JY05). JY04 
underwent Suzuki Coupling. Ar (g) was bubbled into a mixture of JY04 (1.25 g, 3.65 mmol), 
4-nitrophenylboronic acid (0. 731 g, 4.38 mmol), and K2CO3 (1.26 g, 9.12 mmol) in 
toluene/ethanol (3/1 ratio, 20 ml). Pd(PPh3)4 (84.09 mg) was added and the reaction vessel 
was wrapped with tin foil to avoid exposure to light. The mixture was stirred at 98 °C 
overnight. The mixture was diluted with EtOAc and washed with water and brine. The 
organic layer was dried with sodium sulfate and evaporated. The crude compound was 
purified by flash chromatography on a silica gel column using Hex/EtOAc (5:5) as the eluent 
to give 561 mg of the title material in 34.9% yield (yield of the last two steps from JY03 to 
JY05). 
 
4-((1-(Cyclohexylmethyl)piperidin-4-ylidene)(phenyl)methyl)aniline (JY06). JY05 
underwent reduction at the nitro group. JY05 (0.56 g, 1.44 mmol) was dissolved in MeOH. 
10% Pd/C (58.82 mg) was added to suspension. The mixture was hydrogenated at 40 PSI for 
4 hours. The mixture was filtered and the filtrate was diluted with EtOAc and washed with 
water and brine. The organic layer was dried with sodium sulfate and evaporated to yield 178 
mg of the title material as a yellow oil in 31.8 % yield. 
 
1-(4-((1-(Cyclohexylmethyl)piperidin-4-ylidene)(phenyl)methyl)phenyl)-2,3-bis(tert-
butoxycarbonyl)guanidine (JY07). JY06 underwent alkylation at the amino group. JY06 
(0.178 g, 0.46 mmol), 1,3-bis(tert-butoxycarbonyl)-2-methylthiopseudourea (0.15 g, 0.51 
mmol), HgCl2 (0.14 g, 0.51 mmol) were suspended in DCM (12 ml) and TEA (0.2 ml) and 
stirred for a week. The mixture was diluted with EtOAc and washed with water and brine. 
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The organic layer was dried with sodium sulfate and evaporated. The crude compound was 
purified by flash chromatography on a silica gel column using Hex/EtOAc (8:2) as the eluent 
to give 141 mg of the title material as a white solid in 51.6% yield. 
 
1-(4-((1-(Cyclohexylmethyl)piperidin-4-ylidene)(phenyl)methyl)phenyl)guanidine 
(JY08). JY07 underwent deprotection. JY07 (0.14 g, 0.24 mmol) was dissolved in DCM (1.0 
ml). 2.0 M HCl in diethylether (1.5 ml) was added and the mixture was stirred overnight at rt. 
The mixture was subsequently evaporated to yield 85 mg of the title material as a white solid 
in 89.8% yield. 1H NMR (400 MHz, DMSO-d6) δ 10.10 (s, 1H, NH), 10.03 (d, J = 8.5 Hz, 
1H, NH), 7.53 (s, 4H, 2 x NH2), 7.34 (t, J = 7.3 Hz, 2H, 2 x ArCH), 7.26 (t, J = 7.3 Hz, 1H, 
ArCH), 7.23 – 7.14 (m, 4H, 4 x ArCH), 7.14 (d, J = 7.5 Hz, 2H, 2 x ArCH), 3.54 – 3.42 (m, 
2H, CH2CH2N (signal from HSQC)), 3.09 – 2.92 (m, 2H, CH2CH2N), 2.89 (s, 2H, 
CHCH2N), 2.73 – 2.58 (m, 2H, CH2CH2N), 2.57 – 2.39 (m, 2H, CH2CH2N), 1.85 – 1.69 (m, 
3H, 1 x CH2, 1 x CH), 1.70 – 1.52 (m, 2H, 1 x CH2), 1.31 – 1.04 (m, 4H, 2 x CH2), 1.03 – 
0.78 (m, 2H, 1 x CH2); 13C NMR (101 MHz, DMSO-d6) δ 156.3 (C(NH2)2), 141.4 (ArC), 
139.5 (ArC), 137.3 ((Ar)2C=C), 134.4 ((Ar)2C=C), 130.9 (2 x ArCH), 130.6 (ArC), 129.6 (2 
x ArCH), 128.9 (2 x ArCH), 127.5 (ArCH), 124.5 (2 x ArCH), 62.1 (CHCH2N), 53.3 
(CH2CH2N), 53.2 (CH2CH2N), 32.6 (CHCH2N), 31.0 (2 x CH2), 28.1 (CH2CH2N), 28.0 
(CH2CH2N), 25.9 (1 x CH2), 25.4 (2 x CH2). MS (ESI+) 403.50 (M+H)+  
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7.2 BIOLOGY 
Assay condition for the binding affinity assay and functional assay reported in Table 
7-1 and 7-2 respectively. The assay conditions are as reported in Tables 7-1 and 7-2. All 
biological assays were performed by individuals in Core C of the BioMolecular Science 
Department at the University of Mississippi. 
JY08 was functionally evaluated only at the MOR after assessment of the results from 
the binding affinity assay. Due to the low selectivity and affinity for the KOR and DOR, 
functional assay of JY08 at those receptors were not tested.  
 
Table 7-1. Opioid Receptor Binding Assay Parameters 
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Table 7-2. Opioid Receptor Functional Assay Parameters 
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Mass Spectroscopy of JY08 
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13C NMR of JY08 
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1H NMR of JY08 
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
f1
 (
pp
m
)
-1
00
010
0
20
0
30
0
40
0
50
0
60
0
70
0
80
0
90
0
10
00
11
00
2.19
3.96
1.08
2.06
2.99
4.24
2.23
2.15
2.22
2.14
3.43
1.16
2.10
3.77
1.12
0.83
0.89
0.92
0.94
0.95
0.98
1.09
1.12
1.17
1.21
1.23
1.58
1.61
1.64
1.67
1.75
1.78
1.80
1.82
2.44
2.47
2.50 DMSO-d6
2.50
2.50
2.55
2.61
2.64
2.68
2.70
2.89
2.96
2.99
3.01
3.03
7.14
7.15
7.17
7.19
7.20
7.20
7.21
7.21
7.25
7.26
7.28
7.33
7.35
7.37
7.53
10.02
10.05
10.11
7.
1
7.
2
7.
3
7.
4
7.
5
7.
6
f1
 (
pp
m
)
2.14
3.43
1.16
2.10
3.77
7.14
7.15
7.17
7.19
7.20
7.20
7.21
7.21
7.25
7.26
7.28
7.33
7.35
7.37
7.53
0.
8
1.
0
1.
2
1.
4
1.
6
1.
8
2.
0
2.
2
2.
4
2.
6
2.
8
3.
0
3.
2
f1
 (
pp
m
)
2.19
3.96
1.08
2.06
2.99
4.24
2.23
2.15
2.22
0.89
0.92
0.94
0.95
0.98
1.09
1.12
1.17
1.21
1.23
1.58
1.61
1.64
1.67
1.75
1.78
1.80
1.82
2.44
2.47
2.50 DMSO-d6
2.50
2.50
2.55
2.61
2.64
2.68
2.70
2.89
2.96
2.99
3.01
3.03
